Vimarsana
Biggest News Aggregation in the World

Page 4 - Term Efficacy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Term Efficacy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Term Efficacy Today - Breaking & Trending Today

AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week® - Vimarsana News

AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

Published: May 6, 2023

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will present 29 abstracts during the 2023 Digestive Disease Week (DDW) Annual Meeting, May 6-9, 2023,...

Source: prnewswire.com
Related Topics:
United StatesUpadacitinib PharmacokineticCeline GoldbergerSociety For Surgery Of The Alimentary TractExchange CommissionBoehringer IngelheimAbbvie IncAmerican Society For Gastrointestinal EndoscopyMotility Disorders Research ForumDrug AdministrationAmerican Gastroenterological AssociationIronwood PharmaceuticalsClinical Trials To Guide Care Research ForumResearch ForumDisease WeekAnnual MeetingReal World DataClinical TrialsGuide CareImproves Endoscopic OutcomesSeverely Active CrohnDisease IrrespectivePrevious FailureClinical RespondersDisease Receiving
AbbVie Showcases Strength of Dermatology Portfolio with New Data Presented at the 2023 AAD Annual Meeting - Vimarsana News

AbbVie Showcases Strength of Dermatology Portfolio with New Data Presented at the 2023 AAD Annual Meeting

Published: March 13, 2023

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will present more than 20 abstracts, including one late-breaking presentation during the 2023 American...

Source: prnewswire.com
Related Topics:
Mississippi RiverUnited StatesNew OrleansHidradenitis SuppurativaCeline GoldbergerBoehringer IngelheimExchange CommissionAmerican Academy Of DermatologyAbbvie IncPoster CenterAnnual MeetingAll TimesPsoriasis Patients SwitchingRisankizumab AfterIxekizumab AfterBreaking Oral PresentationTerm SafetyPlaque PsoriasisInterim AnalysisTerm Real World Treat To Target Skin ClearanceSevere PsoriasisCorevitas PsoriasisModerate To Severe Plaque Psoriasis OverPrior BiologicWorld Switch Rates
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates - Vimarsana News

Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates

Published: March 2, 2023

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...

Source: prnewswire.com
Related Topics:
United StatesSalt Lake CityLinda NeumanAeglea BiotherapeuticsJeffrey GoldbergCortney CaudillExchange CommissionEuropean Medicines AgencyDrug AdministrationPrnewswire Aeglea Biotherapeutics IncAeglea Biotherapeutics IncClassical HomocystinuriaImmedica PharmaMarketing Authorization ApplicationFast Track DesignationLatin AmericaClinical Genetics MeetingTerm EfficacyMiddle EastSupply AgreementBiologics License ApplicationInvestigational New Drug EnablingDrug DesignationPediatric DiseaseFast Track
New TREMFYA® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis - Vimarsana News

New TREMFYA® (guselkumab) Data Show an Overall Clinical Response Rate of Approximately 80 Percent in a Phase 2b Induction Study of Adults with Moderately to Severely Active Ulcerative Colitis

Published: October 24, 2022

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2b QUASAR Induction Study 1 in adults with...

Source: prnewswire.com
Related Topics:
United StatesSpring HouseBritish ColumbiaCraig StoltzBurrillb CrohnBrucee SandsJan WehkampAmerican College Of Gastroenterology Annual MeetingCrohn Colitis FoundationJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonAmerican College Of GastroenterologyJapan PharmaceuticalsNone Of The Janssen Pharmaceutical CompaniesNational Institutes Of HealthExchange CommissionIcahn School Of Medicine At Mount SinaiCompanies Of JohnsonEuropean Medicines AgencyDevices AgencyCanadian Agency For Drugs Technologies In HealthCrohn Colitis Foundation Of AmericaGastroenterology Annual MeetingAnnual Scientific Meeting
Urovant Sciences, Inc.: Urovant Sciences Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting - Vimarsana News

Urovant Sciences, Inc.: Urovant Sciences Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting

Published: May 15, 2022

New analyses of data from the Phase 3 EMPOWUR Extension Study of GEMTESA (vibegron) 75 mg provided additional insight into the long-term effects of the product. These data were featured in podium

Source: finanznachrichten.de
Related Topics:
United StatesSumitovant BiopharmaSumitomo PharmaMaya FrutigerAlana Darden PowellDavid StaskinJeffrey FrankelDrug AdministrationAmerican Urological AssociationUrovant Sciences GmbSeattle Urology Research CenterCorporate CommunicationsTufts University School Of MedicineUs Public HealthUrovant SciencesSumitovant Biopharma LtdHead Of Corporate CommunicationsPatient Global ImpressionNew OrleansSef KurstjensExecutive Vice PresidentChief Medical OfficerMedical DirectorTerm EfficacyOveractive Bladder